炎症性肠病的治疗与管理进展

Abstract
Figure/Table
References (30)
Related Citation (15)

Download: PDF (615 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the intestine with a tendency to relapse for life, which requires long-term medication and the cost is expensive. Based on the latest research progress in the treatment and management of IBD, this paper starts from several key points, involving the optimized treatment of 5-aminosalicylic acid (5-ASA) of IBD, biological agents and immunomodulatory therapy, the psychotherapy scheme, the intestinal microflora treatment scheme, and 5S principles in IBD management, in order to enhance the understanding of IBD and improve the level of treatment and management of IBD among grass-roots physicians.

Key words： Inflammatory bowel disease Treatment Management Grass-roots

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FENG Gong1 MI Man1 LI Xueping1 LIU Manling1 FAN Liping1 NIU Chunyan2

Cite this article:

FENG Gong1 MI Man1 LI Xueping1 LIU Manling1 FAN Liping1 NIU Chunyan2. Progress in the treatment and management of inflammatory bowel disease[J]. 中国医药导报, 2019, 16(8): 39-42.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I8/39

[1] 中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见（2018年，北京）[J].中华消化杂志，2018，38（5）：292-311.
[2] Ng SC，Zeng Z，Niewiadomski O，et al. Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia [J]. Gastroenterology，2016，150（1）：86-95.
[3] 中华医学会消化病学分会炎症性肠病学组.建立全国通用的炎症性肠病诊治过程的关键性质量控制指标的共识意见[J].中华炎性肠病杂志，2017，1（1）：12-19.
[4] Bressler B，Marshall JK，Bernstein CN，et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis：the Toronto consensus [J]. Gastroenterology，2015，148（5）：1035-1058.
[5] 张玉洁，梁洁，吴开春.炎症性肠病诊断与治疗的共识意见（2018年，北京）溃疡性结肠炎部分解读[J].中华消化杂志，2018，38（5）：312-314.
[6] Roberta P，Claudio C，Andrea C，et al. A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis [J]. Dig Liver Dis，2015，47（11）：933-937.
[7] Suzuki Y，Iida M，Ito H，et al. Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis：a multicenter，randomized，double-blind，parallel-group study [J]. Intest Res，2016，14（1）：50-59.
[8] Doherty G，Katsanos KH，Burisch J，et al. European Crohn′s and Colitis Organisation Topical Review on Treatment Withdrawal （′Exit Strategies′） in Inflammatory Bowel Disease [J]. J Crohns Colitis，2017，12（1）：17-31.
[9] Osterman MT，Aberra FN，Cross R，et al. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis [J]. Clin Gastroenterol Hepatol，2014，12（11）：1887-1893.
[10] Esser D，Cornillie F，Diamond RH，et al. On the updated ECCO consensus guidelines for medical management of Crohn′s disease [J]. J Crohns Colitis，2011，5（2）：165-166.
[11] Derijks LJJ，Wong DR，Hommes DW，van Bodegraven AA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease [J]. Clin Pharmacokinet，2018，57（9）：1075-1106.
[12] Kempster SL，Kaser A. α4β7 integrin：beyond T cell trafficking [J]. Gut，2014，63（9）：1377-1379.
[13] Coskun M，Vermeire S，Nielsen OH. Novel Targeted Therapies for Inflammatory Bowel Disease [J]. Trends Pharmacol Sci，2017，38（2）：127-142.
[14] Danese S，Grisham MB，Hodge J，et al. JAK inhibition using tofacitinib for inflammatory bowel disease treatment：a hub for multiple inflammatory cytokines [J]. Am J Physiol Gastrointest Liver Physiol，2016，310（3）：155-162.
[15] Danese S，Neurath M，Kopon A，et al. OP006 Apremilast for active ulcerative colitis：a phase 2，randomised， double-blind，placebo-controlled induction study [J]. J Crohns Colitis，2018，12（supple_1）：S004-S004.
[16] 中华医学会消化病学分会炎症性肠病学组.抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识（2017）[J].协和医学杂志，2017，8（4/5）：239-243.
[17] 中华医学会消化病学分会炎症性肠病学组.抗肿瘤坏死因子-α单克隆抗体治疗炎症性肠病的专家共识（2017）[J].中华消化杂志，2017，37（9）：577-580.
[18] Gomollón F，Dignass A，Annese V，et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn′s disease 2016：part 1：diagnosis and medical management [J]. J Crohns Colitis，2017，11（1）：3-25.
[19] Yarur AJ，Kubiliun MJ，Czul F，et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy [J]. Clin Gastroenterol Hepatol，2015，13（6）：1118-1124.
[20] Regueiro M，Greer JB，Szigethy E. Etiology and Treatment of Pain and Psychosocial Issues in? Patients With Inflammatory Bowel Diseases [J]. Gastroenterology，2017， 152（2）：430-439.
[21] D′Odorico I，Di BS，Monticelli J，et al. Role of fecal microbiota transplantation in inflammatory bowel disease [J]. J Dig Dis，2018，19（6）：322-334.
[22] Paramsothy S，Kamm MA，Kaakoush NO，et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis：a randomised placebo-controlled trial [J]. Lancet，2017，389（10 075）：1218-1228.
[23] Rossen NG，Fuentes S，van der Spek MJ，et al. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis [J]. Gastroenterology，2015，149（1）：110-118.
[24] K?觟nig J，Siebenhaar A，H?觟genauer C，et al. Consensus report：faecal microbiota transfer-clinical applications and procedures [J]. Aliment Pharmacol Ther，2016，45（2）：222-239.
[25] Cammarota G，Ianiro G，Tilg H，et al. European consensus conference on faecal microbiota transplantation in clinical practice [J]. Gut，2017，66（4）：569-580.
[26] Ding NS，Hart A，De CP. Systematic review：predicting and optimising response to anti-TNF therapy in Crohn′s disease-algorithm for practical management [J]. Aliment Pharmacol Ther，2016，43（1）：30-51.
[27] Matsuoka K，Kobayashi T，Ueno F，et al. Evidence-based clinical practice guidelines for inflammatory bowel disease [J]. J Gastroenterol，2018，53（3）：305-353.
[28] Hibi T，Panaccione R，Katafuchi M，et al. The 5C Concept and 5S Principles in Inflammatory Bowel Disease Management [J]. J Crohns Colitis，2017，11（11）：1302-1308.
[29] Cesarini M，Collins GS，R?觟nnblom A，et al. Predicting the Individual Risk of Acute Severe Colitis at Diagnosis [J]. J Crohns Colitis，2017，11（3）335-341.
[30] He Y，Mao R，Chen F，et al. Thalidomide induces clinical remission and mucosal healing in adults with active Crohn′s disease：a prospective open-label study [J]. Therap Adv Gastroenterol，2017，10（5）：397-406.